Payment overview · 2025
General Payments
$1,320.48
67 reported records · 23 companies
Healthcare provider profile · identity verified
Michael D Slater, DO
Allopathic & Osteopathic Physicians|Family Medicine · AMHERST, NY · NPI 1962451666
Verified facts
What the public records show
CMS Open Payments records show Michael D Slater, DO received $1,320.48 in general payments during 2025 across 67 reported records.
GlaxoSmithKline, LLC. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $199.52 | 15.1% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $183.36 | 13.9% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.03 | 10.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $112.15 | 8.5% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.17 | 6.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.18 | 5.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.40 | 4.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $52.87 | 4.0% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$51.66 | 3.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $51.04 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.39 | 3.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.97 | 3.6% | 3 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $31.85 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.99 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.08 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.55 | 1.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.24 | 1.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.78 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.86 | 1.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.32 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.60 | 1.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.23 | 1.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.24 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,320.48 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $199.52 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $147.23 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.25 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.51 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $112.15 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $109.93 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $90.32 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $66.25 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.18 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.40 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $52.87 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $51.66 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.39 | 3 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 123 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 35 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 545 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 527 | 143 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 468 | 142 |
| Lisinopril | Lisinopril | 362 | 112 |
| Metformin Hcl | Metformin Hcl | 351 | 95 |
| Gabapentin | Gabapentin | 347 | 68 |
| Omeprazole | Omeprazole | 329 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 67 |
| Losartan Potassium | Losartan Potassium | 295 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 273 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 272 | 80 |
| Simvastatin | Simvastatin | 217 | 49 |
| Famotidine | Famotidine | 182 | 47 |
| Baclofen | Baclofen | 180 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 48 |
| Ibuprofen | Ibuprofen | 147 | 42 |
| Alendronate Sodium | Alendronate Sodium | 141 | 35 |
| Jardiance | Empagliflozin | 140 | 35 |
| Metformin Hcl Er | Metformin Hcl | 140 | 35 |
| Furosemide | Furosemide | 127 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 16 |
| Eliquis | Apixaban | 123 | 33 |
| Potassium Chloride | Potassium Chloride | 115 | 23 |
| Atenolol | Atenolol | 111 | 31 |
| Buspirone Hcl | Buspirone Hcl | 108 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 33 |
| Azithromycin | Azithromycin | 102 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 31 |
| Trazodone Hcl | Trazodone Hcl | 96 | 25 |
| Ezetimibe | Ezetimibe | 95 | 28 |
| Tramadol Hcl | Tramadol Hcl | 95 | 26 |
| Celecoxib | Celecoxib | 89 | 16 |
| Glipizide | Glipizide | 88 | 23 |
| Trulicity | Dulaglutide | 88 | 17 |
| Methylprednisolone | Methylprednisolone | 85 | 36 |
| Prednisone | Prednisone | 80 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 16 |
| Allopurinol | Allopurinol | 76 | 21 |
| Montelukast Sodium | Montelukast Sodium | 74 | 21 |
| Sertraline Hcl | Sertraline Hcl | 72 | 18 |
| Glipizide Er | Glipizide | 71 | 14 |
| Carvedilol | Carvedilol | 69 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 14 |
| Amoxicillin | Amoxicillin | 68 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 68 | suppressed |
| Glimepiride | Glimepiride | 66 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 21 |
| Spironolactone | Spironolactone | 61 | 17 |
| Alprazolam | Alprazolam | 60 | 13 |
| Enalapril Maleate | Enalapril Maleate | 60 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 16 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 18 |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Ozempic | Semaglutide | 56 | 17 |
| Xarelto | Rivaroxaban | 56 | 14 |
| Pregabalin | Pregabalin | 54 | 11 |
| Ramelteon | Ramelteon | 54 | 16 |
| Bumetanide | Bumetanide | 53 | 13 |
| Clonazepam | Clonazepam | 53 | 11 |
| Fenofibrate | Fenofibrate | 53 | 11 |
| Lovastatin | Lovastatin | 52 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | 11 |
| Hydrocortisone | Hydrocortisone | 51 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 51 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Irbesartan | Irbesartan | 47 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Finasteride | Finasteride | 44 | suppressed |
| Nystatin | Nystatin | 44 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | 15 |
| Fluconazole | Fluconazole | 40 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 11 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 12 |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Valsartan | Valsartan | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 22 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 15 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | suppressed |
| Diazepam | Diazepam | 19 | 11 |
| Linzess | Linaclotide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,320.48 · 67 records | GlaxoSmithKline, LLC. | ACCRUFER, AIRSUPRA, BREZTRI, CONTRAVE, Cologuard Collection Kit, Descovy, ELIQUIS, ENTRESTO, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, MINIMED 780G, NURTEC ODT, Ohtuvayre, Omnipod, Ozempic, Rybelsus, TRELEGY ELLIPTA, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error